Pet DRx (Nasdaq: VETS) shareholders are investigating possible breaches of fiduciary duty and other corporate violations by the board of directors of Pet DRx. The investigation arises from Pet DRx’s entering into a merger agreement with VCA Antech.
Under the terms of the buyout Pet DRx shareholders will receive $.34-.36 in cash for each share of Pet DRx common stock they own. Shareholders are questioning the deal based on the fact Pet DRx common stock traded at $.50 as recently as February of this year.
Shareholders are investigating potential breaches of fiduciary duty and other violations concerning the transaction’s approval by Pet DRx’s board of directors, and in particular whether Pet DRx’s board undertook a fair and complete process to attain the highest value for Pet DRx’s public shareholders.
If you are a Pet DRx shareholder and wish to speak with us about your legal rights or are interested in participating in litigation concerning the Pet DRx merger, please complete the following form or call us at 1-877-573-0007.